Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
Key claim: A Phase 1b open-label study is evaluating the safety, pharmacokinetics, and preliminary efficacy of pelabresib added to ruxolitinib in Japanese myelofibrosis patients.
Abstract
This Phase 1b, multicenter, open-label study aims to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of pelabresib as add-on to ruxolitinib in Japanese patients with myelofibrosis (MF).
Why this matters
Pelabresib + ruxolitinib is a leading combination strategy in myelofibrosis, and bridging studies in Japanese patients are needed to support regional regulatory pathways and surface any PK or tolerability differences in East Asian cohorts. Although novelty is modest, the data will inform global dosing strategy and the broader question of whether MF combination regimens behave consistently across populations.